A randomized, controlled pilot study of MDMA (±3,4-Methylenedioxymethamphetamine)- assisted psychotherapy for treatment of resistant, chronic Post-Traumatic Stress Disorder (PTSD)

Three doses of MDMA (125mg) showed the most promise in this pilot study (n=12) of MDMA psychotherapy for PTSD. The CAPS score (PTSD measure) was just shy of significance, self-reported improvement was significant.

Abstract

“Psychiatrists and psychotherapists in the US (1970s to 1985) and Switzerland (1988–1993) used MDMA legally as a prescription drug, to enhance the effectiveness of psychotherapy. Early reports suggest that it is useful in treating trauma-related disorders. Recently, the first completed pilot study of MDMA-assisted psychotherapy for PTSD yielded encouraging results. Designed to test the safety and efficacy of MDMA-assisted psychotherapy in patients with treatment-resistant PTSD; our randomized, double-blind, active-placebo controlled trial enrolled 12 patients for treatment with either low-dose (25 mg, plus 12.5 mg supplemental dose) or full-dose MDMA (125 mg, plus 62.5 mg supplemental dose). MDMA was administered during three experimental sessions, interspersed with weekly non-drug-based psychotherapy sessions. Outcome measures used were the Clinician-Administered PTSD Scale (CAPS) and the Posttraumatic Diagnostic Scale (PDS). Patients were assessed at baseline, three weeks after the second and third MDMA session (end of treatment), and at the 2-month and 1-year follow-ups. We found that MDMA-assisted psychotherapy can be safely administered in a clinical setting. No drug-related serious adverse events occurred. We did not see statistically significant reductions in CAPS scores (p = 0.066), although there was clinically and statistically significant self-reported (PDS) improvement (p = 0.014). CAPS scores improved further at the 1-year follow-up. In addition, three MDMA sessions were more effective than two (p = 0.016).”

Authors: Peter Oehen, Rafael Traber, Verena Widmer & Ulrich Schnyder

Notes

This study was one of the first to apply the double-blind placebo-controlled study design to MDMA-assisted therapy for PTSD. It is published (2012) shortly after Mithoefer et al. (2010) and served as a confirmation of the previous results (which it partly did, but no significance on the CAPS score) and test with another therapy team. Different in this study was the use of an active placebo (12.5mg MDMA) vs an inactive placebo.

In conclusion the authors recommend limiting the number of follow-up sessions, but expanding the introductory sessions from two to three (to strengthen the therapeutic alliance).

This study was supported by MAPS.

Become a psychedelic insider!

With a Blossom membership you will always be in the know.

📰 Twice a week newsletter about the psychedelic research

✔️ Unlimited access to our database and original articles

🖊️ Add (private) notes and comments to each page

See all benefits
0 Comments
Inline Feedbacks
View all comments
0
Would love your thoughts, please comment.x
()
x